Israeli Startup Patents Treatment For Neurological Disorder

Petach Tikva-based startup BrainStorm has been granted three foreign patents for its neurological disorder treatment platform NurOwn and NurOwn-Exosomes.

BrainStorm Cell Therapeutics is biotech company that develops stem cell therapy for neurogenerative diseases such as Amyotrophic lateral sclerosis (ALS), multiple sclerosis and parkisons disease.

NurOwn is a platform that investigates therapeutic approaches to target diseases that damage the nervous system such as ALS.

BrainStorm takes a patient’s cells from their bone marrow and then isolates and cleans Mesenchymal stem cells, which have the ability to self-renew.

This cells are grown in a lab using NurOwn technology and become known as NurOwn cells (MSC-NTF). NurOwn cells are inserted back into the patient, through the spine, and then they help nerve cells grow, reproduce and survive, as well as reduce the production of inflammation.

The three patents are from Europe, Australia and Israel for BrainStorm’s NurOwn and NurOwn-Exosomes platforms.

The European patent is for a method of checking weather a cell group is suitable for treating ALS.

The Australian patent is for isolated Exosomes, which are tiny structure inside a cell that can hold and transport various substances, such as proteins and carbohydrates. The Israeli patent is also for the isolated Exosomes.

“The recent acquisition of the European patent for our unique MSC-NTF cell population marks an important step in safeguarding our proprietary NurOwn technology,” said Chaim Lebovits, BrainStorm’s CEO.

“Securing this European patent, alongside our existing patents in the US, Canada, Israel, Brazil, and Japan, enhances our capability to forge new global commercial partnerships, further expanding the reach of NurOwn.”